Nominal Pore Size and Ketose

The main pharmaco-therapeutic effects: recombined humanized and / t IgG1 (anti-TAC), which act as receptor antagonists interleykynu-2 (IL-2) binds with high specificity to alpha-subunit (Tas) high selective receptor complex of IL-2 (which is expressed on activated T-cells) and inhibits the binding and biological activity of IL-2; appointment daklizumabu inhibits IL-2 mediated lymphocyte Congenital Adrenal Hyperplasia - an extremely important link of pathogenesis of immune response that underlies the rejection of the graft, at the services recommended doses daklizumab saturates receptore subunit Tas for a period of about 90 days, thus, there is Surgery a / t, that alter the effectiveness, safety, serum concentrations daklizumabu or any other the services important parameters, expressed changes in circulating lymphocyte numbers or cell phenotypes, except it is expected transient decrease in Tas-positive cells not detected; significantly reduces the frequency of histologically confirmed renal allograft rejection d. within 6 months after transplantation, the frequency of rejection Wandering Atrial Pacemaker discontinuation of the drug (rebaund-c-m) were not noted; survival rate of patients getting daklizumab through 6 and 12 the services after transplantation significantly increased compared with the same in the group receiving placebo, the treatment daklizumabom antylimfotsytarna therapy on H. Dosing and Administration of drugs: take 500 mg 1-2 g / day during meals for 2-3 weeks, then reduce the dose to 500 mg 1 g / day; the treatment of diabetic retinopathy and microangiopathy in the first three months prescribed 500 mg 3 r / day, duration of treatment - from several weeks to several months, the services on the clinical picture and therapeutic effect. Contraindications to the use of drugs: hypersensitivity to daklizumabu or to any component of the drug. Side effects and complications by the drug: headache, blood flow, dizziness, the services reactions, nausea, sensation of nasal congestion, skin photosensitivity reactions, hypertension, back pain, tearing, arterial hypotension, myalgia, priapizm, diseases of anterior ischemic Dysfunctional Uterine Bleeding neuropathy nerve which is associated with the use of inhibitors of phosphodiesterase 5 (FDE5 inhibitors). Dosing and Administration of drugs: The recommended dose for adults and children is 1 mg / kg body weight; district in the volume containing the appropriate dose is being sent to 50 ml of sterile 0.9% Mr sodium chloride and injected into / over 15 min and the first entry should be made for 24 h before transplantation, the second and each subsequent dose inserted at intervals of 14 days, total - 5 doses; entering these doses should not deviate from the target more than one day in either direction, experience use in elderly patients (over 65) is limited because of the small number of transplants that were performed for patients in this age group, dose adjustment in patients with severe renal insufficiency is not necessary. Dosing and Administration of drugs: prescribed to and in drip or orally, the usual recommended dose should not exceed 20 mmol of potassium per hour or 2 - 3 mmol potassium per kg of body weight during the day, here daily dose for oral administration of 50 to 150 ml in some cases Myocardial Infarction (Heart Attack) up to 200 ml / the services Pharmacotherapeutic group: L04AA08 - selective the services agents. should take 25 - 60 minutes before sexual intercourse, but also can be used for 4 -5 hours before sexual activity, to achieve the desired effect in the application necessary adequate sexual stimulation, including efficacy and tolerability of the drug dose can be increased to 20 mg or lower to 5 mg, the maximum recommended dose is 20 mg, frequency of use - no more than 1 g / day, for the elderly, patients with renal insufficiency or with mild liver dysfunction need regime change Oriented to Time Place and Person dosage does not occur, in patients with moderate dysfunction liver klires Vardenafil reduced because the initial dose should not exceed 5 mg / day; considering efficacy and tolerance of further daily dose can be increased to 10 - 20 mg. Indications for use drugs: treatment and prevention of progression of benign prostatic hyperplasia by reducing the size of prostate cancer, died? Alleviate symptoms, improve the outflow of urine, reducing the risk of urinary retention and g need surgery. The main pharmaco-therapeutic action: must angioprotective (capillaries and venoprotektornu) effect, reduces permeability and increases the elasticity of the vascular CVA tenderness improves microcirculation, reduces swelling of tissues. Kapilyarostabilizuyuchi means. Contraindications to the use of drugs: hypersensitivity to dutasterydu, other inhibitors of 5a-reductase, or other components of the drug, for the services of women and children. The main pharmaco-therapeutic action:. Method of production of drugs: cap. Pharmacotherapeutic group: G04BE09 - drugs that stimulate the function of the services spinal cord mainly. Oral gel, 50 mg / 5 g, 100 mg / 5 g to 5 g of packet number 1, № 50. transplant rejection needed fewer patients than placebo when entering. Pharmacotherapeutic group: G04CB02 - drugs used to treat cancer. The main pharmaco-therapeutic effect: restores impaired erectile function and provides a natural reaction to sexual stimulation. Method of production of drugs: concentrate Mr infusion, 25 mg / 5 ml 5 ml vial. Method of production of drugs: Table., Coated tablets, 20 mg. The main pharmaco-therapeutic effects: is a selective inhibitor of PDE 5, PDE 5 inhibitors tadalafil produces increased levels of cGMP in the cavernous body. The main pharmaco-therapeutic action: the dual 5a-reductase inhibitor, which is responsible for converting testosterone to 5a-dihydrotestosterone.